Acquisition Completed
Day One Biopharmaceuticals acquisition of Mersana Therapeutics
NASDAQ: MRSN · US$25.00 per share
Advisers
Day One Biopharmaceuticals
Acquirer
- Financial adviser
- Legal adviser
- Target
- Mersana Therapeutics
- Acquirer
- Day One Biopharmaceuticals
- Target based in
- United States
- Buyer based in
- United States
- Completed
- 6 Jan 2026
- Sector
- Biotech
- Tags
- Biotech, Oncology, Drug Development
In the league tables
Similar deals
- GSK acquisition of trispecific T cell-engager (TCE) asset Sep 2026 · US$750m · Biotech
- Passage Bio and Remix Therapeutics merger Jun 2026 · Biotech
- GSK acquisition of Nuvalent Jun 2026 · US$11bn · Biotech
- Treeline Biosciences and Standard BioTools merger Jun 2026 · US$460m · Biotech
- Rallybio acquisition of Avenzo Therapeutics Jun 2026 · Biotech